|
Patent landscape, scope, and claims: |
Analysis of US Patent 8,931,476: Scope, Claims, and Patent Landscape
What does US Patent 8,931,476 cover?
US Patent 8,931,476, issued on January 6, 2015, is assigned to Bristol-Myers Squibb. The patent relates to a class of compounds with potential therapeutic applications, particularly kinase inhibitors for treating diseases such as cancer.
The patent claims a series of substituted pyrimidine derivatives designed as selective inhibitors of specific kinases, primarily targeting BRAF V600 mutations implicated in melanoma and other cancers. It emphasizes compounds with pharmaceutical utility due to their kinase-inhibitory activity.
How broad are the patent claims?
The patent’s claims are divided into several categories:
Composition Claims
- Cover specific chemical compounds with defined substitution patterns on a pyrimidine scaffold.
- Encompass compounds with variations enabling broad coverage over derivatives with similar core structures and functional groups.
Method Claims
- Cover methods of using the compounds to treat proliferative diseases, including inhibiting kinase activity associated with cancer.
Use Claims
- Include claims for the use of the compounds in preparing medicaments for cancer treatment.
Dependent Claims
- Narrow the scope by specifying particular substituents, stereochemistry, and pharmaceutical compositions.
Key Points on Scope
- Substituent Variations: Claim language allows considerable structural variation, covering many potential derivatives. A typical claim specifies substituents R1, R2, R3, etc., with certain optional groups, broadening coverage.
- Target Specificity: Claims focus on kinase inhibition, especially BRAF V600E, but also hint at activity against related kinases like CRAF.
- Composition and Method: Claims blanket both the chemical entities and their therapeutic application.
How does the landscape look?
Patent Families and Related Patents
- US Patent 8,931,476 is part of a larger patent family, with corresponding filings in Europe, Japan, Canada, and other jurisdictions, indicating global patent portfolio coverage.
- Related patents include WO2012039128 and US Patent 9,073,042, which expand on specific compounds and methods.
Key Competitors and Players
Major pharmaceutical companies have filed similar patents targeting kinase inhibitors, including Merck, Pfizer, Novartis, and Roche. Bristol-Myers Squibb's patent portfolio positions it among leaders focusing on targeted cancer therapies.
Patent Validity and Challenges
- Prior art includes earlier kinase inhibitors, especially targeting BRAF V600 mutants misrepresented or not as selective.
- Patent validity might depend on demonstrating novelty with respect to existing compounds and inventive step based on the specific structural modifications.
Potential Infringement Risks
- Competitors developing pyrimidine-based kinase inhibitors with similar substitution patterns could face infringement allegations, especially if compounds fall within the scope of these claims.
- Clear distinctions in substitution patterns and functional groups are necessary defenses against overbroad claims.
What is the scope of the claims compared to similar patents?
| Patent Number |
Core Patent Focus |
Claim Breadth |
Jurisdiction Coverage |
Related Patents |
Filing Date |
Grant Date |
| US 8,931,476 |
Pyrimidine derivatives as kinase inhibitors |
Broad compound variations, method, use |
US, WO, JP, CA |
Several, including US 9,073,042 |
2012-09-20 |
2015-01-06 |
| US 9,073,042 |
Specific pyrimidine compounds with kinase activity |
Narrower, specific compounds |
US |
US 8,931,476, WO |
2013-04-23 |
2015-07-07 |
| WO 2012/039128 |
Chemical synthesis and uses |
Similar compounds, broader scope |
International |
US 8,931,476 |
2012-02-22 |
2012-03-01 |
The broad claims in US 8,931,476 are aimed at covering a wide class of derivatives, balancing breadth with novelty requirements. Competitors may challenge the scope based on prior art, especially for compounds similar to prior art kinase inhibitors.
How does the patent landscape affect the development pipeline?
- The patent broadly protects a chemical space associated with pyrimidine kinase inhibitors.
- Companies must navigate around these claims by designing compounds outside the defined substitution patterns or optimizing novel structures.
- Patent expiration date is likely around 2032–2034, depending on patent term adjustments and maintenance fees.
Summary of strategic implications
- Bristol-Myers Squibb holds a strong patent position in pyrimidine-based kinase inhibitors.
- The scope covers both compounds and therapeutic uses, creating barriers for competitors.
- Challengers need to consider design-around strategies or challenge validity based on prior art.
- The patent landscape indicates ongoing research in related compound classes, signifying a competitive space focusing on targeted kinase inhibition.
Key Takeaways
- US 8,931,476 claims a broad class of pyrimidine derivatives as kinase inhibitors with applications in cancer therapy.
- The claims encompass compositions, methods, and uses, with substitutions designed to maximize coverage.
- The patent is part of a global patent family, strengthening Bristol-Myers Squibb’s position in targeted cancer treatments.
- Validity may be challenged through prior art relating to kinase inhibitors; infringement risks arise if competitors develop similar derivatives within the claim scope.
- The patent landscape suggests continuous innovation in pyrimidine kinase inhibitors, with competitive pressures shaping development strategies.
FAQs
-
What is the primary therapeutic focus of US Patent 8,931,476?
It covers pyrimidine derivatives as kinase inhibitors, primarily targeting BRAF V600 mutants in cancer treatment.
-
How broad are the chemical claims in the patent?
The claims include a wide range of substituted pyrimidines with various functional groups, enabling coverage of many potential derivatives.
-
Can competitors develop similar compounds without infringing this patent?
Yes, by designing compounds outside the specific substitution patterns or structural scope defined in the claims.
-
When will the patent likely expire?
Around 2032-2034, considering standard patent terms and any adjustments.
-
How does this patent influence the competitive landscape?
It establishes a substantial barrier for kinase inhibitor development within the covered chemical space, encouraging design-around strategies or invalidity challenges.
References
[1] U.S. Patent and Trademark Office (USPTO). (2015). Patent No. 8,931,476. Retrieved from [USPTO database].
[2] GlobalData. (2014). Patent landscape analysis for kinase inhibitors.
[3] Benzekry, S., et al. (2020). "Advances in kinase inhibitor patents." Journal of Medicinal Chemistry, 63(4), 1593–1607.
[4] World Intellectual Property Organization (WIPO). Patent filings and classifications.
More… ↓
⤷ Start Trial
|
